Skip to search formSkip to main contentSkip to account menu

denileukin diftitox

Known as: Diphtheria toxin precursor, NAD(+--diphthamide ADP- ribosyltransferase), Interleukin-2 Fusion Protein 
A cytotoxic recombinant protein consisting of interleukin-2 (IL-2) protein sequences fused to diphtheria toxin. The IL-2 protein sequence moiety of… 
National Institutes of Health

Related topics

Related topics

9 relations
2 ML denileukin diftitox 0.15 MG/ML InjectionNCIt Antineoplastic Agent Terminologydenileukin diftitox/dexamethasone

Broader (5)

Antineoplastic AgentsDENILEUKINDiphtheria ToxinInterleukin-2

Narrower (1)

DAB(389)-interleukin 2

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2011
Review
2011
Photochemical internalization of tumor‐targeted protein toxins
Photochemical internalization (PCI) is a method for intracellular delivery of hydrophilic macromolecular drugs with intracellular… 
2007
2007
Phase II study of denileukin diftitox for previously treated indolent non-Hodgkin lymphoma: Final results of E1497
Denileukin diftitox (DD) is approved for treatment of CD-25 expressing cutaneous T-cell lymphomas (CTCL). Initial studies of DD… 
Highly Cited
2004
Highly Cited
2004
Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma.
PURPOSE Denileukin diftitox is a fusion protein combining diphtheria toxin and interleukin-2 (IL-2) that targets tumor cells… 
Review
2004
Review
2004
Current management strategies for cutaneous T-cell lymphoma.
2002
2002
Process development of a recombinant antibody/interleukin-2 fusion protein expressed in protein-free medium by BHK cells.
Highly Cited
2001
Highly Cited
2001
A multicenter dose-escalation trial with denileukin diftitox (ONTAK, DAB(389)IL-2) in patients with severe psoriasis.
BACKGROUND Denileukin diftitox, a fusion protein targeting both malignant and normal activated lymphocytes, has been shown… 
Review
2000
Review
2000
Bexarotene and DAB(389)IL-2 (denileukin diftitox, ONTAK) in treatment of cutaneous T-cell lymphomas: algorithms.
Mycosis fungoides (MF), CD4(+) epidermotropic cutaneous T-cell lymphoma (CTCL), often arises as indolent, inflammatory, chronic… 
Review
1997
Review
1997
Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies.
Highly Cited
1994
Highly Cited
1994
Phase I trial of an interleukin‐2 fusion toxin (DAB486IL‐2) in hematologic malignancies: Complete response in a patient with Hodgkin's disease refractory to chemotherapy
Background. DAB486IL‐2 is a recombinant fusion toxin in which the native diphtheria toxin‐receptor binding‐domain has been… 
1993
1993
A recombinant single chain antibody interleukin-2 fusion protein.
Recombinant interleukin-2 (rIL-2) therapy has been shown to be of value in the treatment of some cases of melanoma and renal cell… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)